O-(2-[18F]fluoroethyl)-l-tyrosine positron-emission tomography/computed tomography (18F-FET PET/CT) is well known in brain tumor management. Our study aimed to identify the prognostic value of 18F-FET PET/CT in high-grade gliomas (HGG) according the current 2016 World Health Organization (WHO) classification.
Patients with histologically proven WHO 2016 HGG were prospectively included. A dynamic 18F-FET PET/CT was performed allowing to obtain 2 static PET frames (static frame 1: 20–40 minutes and static frame 2: 2–22 minutes). We analyzed static parameters (standard uptake value [SUV]max, SUVmean, SUVpeak, TBRmax, TBRmean, tumoral lesion glycolysis, and metabolic tumoral volume) for various isocontours (from 10% to 90%). PET parameters, clinical features, and molecular biomarkers were compared with progression-free survival (PFS) and overall survival (OS) in univariate and multivariate analysis.
Twenty-nine patients were included (grade III n = 3, grade IV n = 26). Mean PFS and OS were, respectively, 8.8 and 13.9 months. According to univariate analysis, SUVmean, SUVpeak, TBRmax, and TBRmean were significantly correlated with OS. In static 1 analysis, TBRmax seemed to be the best OS prognostic parameter (P = .004). In static 2 analysis, TBRmean was the best parameter (P = .01). In static 1 analysis, only SUVpeak was significant (P = .05) for PFS. Good performance status (PS < 2; P < .0001) and extent of resection (P = .019) identified the subgroup of patients with the best OS. Only TBRmax (P = .026) and extent of resection (P = .025) remained significant parameters in multivariate analysis.
Our data suggested that high TBRmax seemed to be the most significant OS independent prognostic factor in patients with newly diagnosed HGG.
Background: Antiangiogenic agents have improved the prognosis of non-squamous nonsmall-cell lung cancers (NSCLCs), even though all the patients are not eligible to receive them because of counterindications linked to the tumor's characteristics or comorbidities. Much less information is available about the eligibility of patients with squamous nonsmall-cell lung cancers (SQ-NSCLCs) to receive antivascular endothelial growth-factor (VEGF) treatments, even though such molecules are being developed for this histology. This study was undertaken to determine the percentage of advanced SQ-NSCLC patients who would be eligible to receive an antiVEGF agent as second-line systemic therapy. Methods: This observational, multicenter, prospective study evaluated advanced SQ-NSCLC patients' criteria for ineligibility to receive an antiVEGF during a multidisciplinary meeting to choose their standard second-line systemic therapy. Results: Among the 317 patients included, 53.6% had at least one ineligibility criterion, and 20% had at least two, with disease extension to large vessels (39.8%), tumor cavitation (20.5%), cardiovascular disease (11%) and/or hemoptysis (7.2%) being the most frequent. Patients with an ECOG performance score of 1/2 had more cardiovascular contraindications that those with scores of 0. Conclusion: Almost half of the SQ-NSCLC patients included in this study would have been eligible to receive an antiVEGF agent. The development of these molecules for these indications should be encouraged.
18 F-fluoroethyltyrosine (FET) is a well-established PET tracer for the imaging of cerebral gliomas. Recent studies reported interest in meningiomas. A study published by Cornelius et al concludes that FET PET may provide additional information for noninvasive grading of meningiomas. Indeed, the combination of tumor background ratio with a cutoff value of 2.3 associated with time activity curve pattern slightly improved the differentiation of high-grade from low-grade meningiomas (accuracy, 92%; P = 0.001). We present the case of a 75-year-old man that underlined the need to confirm the performance of these tools (curve pattern, tumor background ratios) to characterize meningiomas.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.